Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLiang, Lung-Yu-
dc.contributor.authorPatel, Onisha-
dc.contributor.authorJanes, Peter W-
dc.contributor.authorMurphy, James M-
dc.contributor.authorLucet, Isabelle S-
dc.identifier.citationOncogene 2019; 38(39): 6567-6584en
dc.description.abstractEph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that drive Eph receptor signalling, and investigates the contribution of intra- and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6. Throughout this review, we carefully analyse and reconcile the existing/conflicting data in the field, to allow researchers to further the current understanding of Eph receptor signalling.en
dc.titleEph receptor signalling: from catalytic to non-catalytic functions.en
dc.typeJournal Articleen
dc.identifier.affiliationDepartment of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australiaen
dc.type.austinJournal Article-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en- Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jan 30, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.